Toggle navigation
Home
Search
Services
Blog
Contact
About
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter
Idec Pharmaceuticals Corporation, San Diego, CA, United States
Search 10 grants from Peter Brams
Search grants from Idec Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Dopamine and the Role of Anterior Cingulate Cortex in Executive Processes
Hypothalamo-brainstem control of sleepiness and arousal
Tropomyosin Interactions in Muscle
Continuing and Future Studies of the Dcct Cohort and Its Samples
CAREER : The Evolution and Genetic Regulation of Sexual Fate in Nematodes
Recently added grants:
Exploring the genetic basis of AD progression
Characterizing the roles of novel soluble GSMs in AD pathology.
Investigatingthe cause of APOE4-associated microglial activation and its resulting neurotoxicityoftauopathy-afflicted neurons
Physical Activity in Underserved Populations: Using Epidemiologic Assessments to Inform Sustainable Intervention
The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036027-02A1
Application #
2072058
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-08-15
Project End
1998-04-30
Budget Start
1996-05-01
Budget End
1997-04-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Idec Pharmaceuticals Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Related projects
NIH 1997
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
NIH 1996
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
Comments
Be the first to comment on Peter Brams's grant